

List of Tables

		Contraction of the second s	
Table No.	Title	Page No.	
2.1	Clinical status of polymeric nanoparticles for drug delivery	28	
	under development.	20	
3.1	Proprietary medications of Pioglitazone HCl	79	
3.2	Proprietary medications of Rosiglitazone maleate	89	
3.3	The specific end groups in the polymer series generated by	98	
	different chain length controllers	20	
4.1	Tests for identification of Pioglitazone HCl.	113	
4.2	Tests for identification of Rosiglitazone maleate.	114	
4.3	Tests for identification of Rosiglitazone base.	114	
4.4	Solubility profile of Pioglitazone HCl, Rosiglitazone maleate	115	
	and Rosiglitazone base in various solvents.	110	
4.5	Infrared spectral assignment of Pioglitazone HCl	116	
4.6	Infrared spectral assignment of Rosiglitazone maleate	116	
4.7	Infrared spectral assignment of Rosiglitazone base	116	
4.8	Mean absorbance values, regressed values and statistical		
	data of the calibration curve for the estimation of	122	
	Pioglitazone HCl in MeOH-ACN at λ_{max} = 268.0 nm		
4.9	Intra-day accuracy and precision of calibration curve of	120	
	Pioglitazone HCl in MeOH-ACN at $\lambda_{max} = 268.0$ nm	123	
4.10	Inter-day accuracy and precision of calibration curve of	400	
	Pioglitazone HCl in MeOH-ACN at $\lambda_{max} = 268.0$ nm	123	
4.11	Mean absorbance values, regressed values and statistical		
	data of the calibration curve for the estimation of		
	Pioglitazone HCl in MeOH-ACN-PBS(pH 7.4)-0.1 N NaOH	124	
	at $\lambda_{\text{max}} = 266.0 \text{ nm}$		
4.12	Intra-day accuracy and precision of calibration curve of		
	Pioglitazone HCl in MeOH-ACN-PBS(pH 7.4)-0.1 N NaOH	125	
	at $\lambda_{\text{max}} = 266.0 \text{ nm}$		
4.13	Inter-day accuracy and precision of calibration curve of		
	Pioglitazone HCl in MeOH-ACN-PBS(pH 7.4)-0.1 N NaOH	125	
	at $\lambda_{\text{max}} = 266.0 \text{ nm}$		
4.14	Mean absorbance values, regressed values and statistical		
	data of the calibration curve for the estimation of	126	
	Rosiglitazone maleate in MeOH at λ_{max} =246.8 nm		
4.15	Intra-day accuracy and precision of calibration curve of		
	Rosiglitazone maleate in MeOH at λ_{max} = 246.8 nm	127	
4.16	Inter-day accuracy and precision of calibration curve of	127	

A 17	Most charteness values, regressed values and statistical	
4.17	deta of the calibration curve for the estimation of	100
	Design the calibration curve for the estimation of P_{curve} is the set of the estimation of P_{curve} is the set of the	120
4.10	Kosiginazone base in ACN-PBS (pH 7.4) at A _{max} =246.2 nm	
4.18	Intra-day accuracy and precision of calibration curve of	129
	Rosiglitazone base in ACN-PBS (pH 7.4) at $\lambda_{max} = 246.2$ nm	
4.19	Inter-day accuracy and precision of calibration curve of	129
	Rosiglitazone base in ACN-PBS (pH 7.4) at λ_{max} =246.2 nm	
5.1	Optimization of formulation parameters for Pioglitazone	141
	formulations prepared by nanoprecipitation method	
5.2	Optimization of formulation parameters for Rosiglitazone	142
	formulations prepared by nanoprecipitation method	
5.3	Optimization of formulation parameters for Pioglitazone	
	formulations prepared by emulsion solvent evaporation method	151
54	Optimization of formulation parameters for Rosiglitazone	
	formulations prepared by emulsion solvent evaporation	152
	method	102
55	Particle size PDL entranment efficiency and zeta potential	
0.0	data of ontimized drug (Pioglitazone / Rosiglitazone) loaded	167
	NPs formulations	107
56	Drug content of Pinglitazona (Resignitazona in their pasa)	
5.0	colution	167
57	The Lingtic nerometers for release of Biggliterone from BIO	
5.7	NB papaparticles in DBC (pH 7.4)	167
50	The kinetic perspectors for release of Displitegene from Th	
5.6	PIO NIP nononanticles in PIS (nH 7.4)	168
50	The kinetic noremeters for release of Desiglitarons from	
0.9	DOC ND nonononticles in DDC (nU 7.4)	168
E 10	The kinghis negroup for four plages of Desiglitations from Th	
5.10	POC NB non-americal in PBC (-11.7.4)	169
E 11	ROS-NP nanoparticles in PBS (pri 7.4)	
5.11	Effect of different cryoprotectants on the particle size and	169
(1	redispersability of PLCA nanoparticles	
0.1	Effect on appearance of optimized formulations of	000
	Pioglitazone and Rosiglitazone at 5°C±2°C during 6 months storage.	209
6.2	Effect on appearance of optimized formulations of	
	Pioglitazone and Rosiglitazone at 25°C±2°C at 60±5% RH	209
	during 6 months storage.	
6.3	Effect on particle size and PDI of optimized nanoparticulate	<u> </u>
· · · · · · · · · · · · · · · · · · ·	formulations of Pioglitazone and Rosiglitazone during 6	210
	00	

	months storage.	
· 6.4	Effect on zeta potential of optimized nanoparticulate	
	formulations of Pioglitazone and Rosiglitazone during 6	211
•	months storage.	
6.5	Effect on drug content of optimized nanoparticulate	
	formulations of Pioglitazone and Rosiglitazone during 6	212
	months storage.	
7.1	Hemolytic profile of PIO & ROS and their formulations	229
7.2	Cytoprotective study of various PIO & ROS formulations	220
	after 48 hrs incubation with β -Amyloid.	229
8.1	Effect of amount of Stannous Chloride on radiolabeling	
	efficiency of PIO and its nanoparticulate formulations with	253
	^{99m} Tc	
8.2	Effect of amount of Stannous Chloride on radiolabeling	
	efficiency of ROS and its nanoparticulate formulations with	253
	^{99m} Tc	
8.3	Effect of pH on radiolabelling efficiency of PIO and its	253
	nanoparticulate formulations with ⁹⁹ mTc	200
8.4	Effect of pH on radiolabelling efficiency of ROS and its	254
	nanoparticulate formulations with 99mTc	201
8.5	Effect of incubation time on radiolabelling efficiency of PIO	254
	and its nanoparticulate formulations with 99mTc	201
8.6	Effect of incubation time on radiolabelling efficiency of PIO	255
	and its nanoparticulate formulations with 99mTc	200
8.7	Biodistribution of PIO-D (Oral)	255
8.8	Biodistribution of PIO-S (nasal)	256
8.9	Biodistribution of PIO-NP (i.v.)	256
8.10	Biodistribution of Tf-PIO-NP (i.v.)	257
8.11	Biodistribution of ROS-S (Oral)	257
8.12	Biodistribution of ROS-S (nasal)	258
8.13	Biodistribution of ROS-S (i.v.)	258
8.14	Biodistribution of ROS-NP (i.v.)	259
8.15	Biodistribution of Tf-ROS-NP (i.v.)	259

,